Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference
Cue Biopharma (Nasdaq: CUE) announced its participation in a fireside chat at the Citizens Life Sciences Conference in New York on May 8, 2025. CEO Daniel Passeri will present from 11:00 AM to 11:25 AM EDT, discussing progress on the company's Immuno-STAT™ platform programs, including the CUE-100 series, CUE-401, and CUE-501. The presentation will highlight their recent partnership with Boehringer Ingelheim for CUE-501, focusing on T cell mediated targeted depletion of specific B cells for treating autoimmune and inflammatory diseases. A live webcast will be available, and the recording will be archived for 30 days on the company's website.
Cue Biopharma (Nasdaq: CUE) ha annunciato la sua partecipazione a una conversazione informale al Citizens Life Sciences Conference a New York il 8 maggio 2025. Il CEO Daniel Passeri presenterà dalle 11:00 alle 11:25 EDT, illustrando i progressi dei programmi basati sulla piattaforma Immuno-STAT™, inclusi la serie CUE-100, CUE-401 e CUE-501. La presentazione metterà in evidenza la recente collaborazione con Boehringer Ingelheim per CUE-501, focalizzata sulla deplezione mirata di specifiche cellule B mediata da cellule T per il trattamento di malattie autoimmuni e infiammatorie. Sarà disponibile una diretta webcast e la registrazione resterà archiviata per 30 giorni sul sito web dell'azienda.
Cue Biopharma (Nasdaq: CUE) anunció su participación en una charla informal en la Citizens Life Sciences Conference en Nueva York el 8 de mayo de 2025. El CEO Daniel Passeri presentará de 11:00 a 11:25 AM EDT, hablando sobre los avances en los programas de la plataforma Immuno-STAT™, incluyendo la serie CUE-100, CUE-401 y CUE-501. La presentación destacará su reciente asociación con Boehringer Ingelheim para CUE-501, enfocada en la depleción específica de células B mediada por células T para tratar enfermedades autoinmunes e inflamatorias. Habrá una transmisión en vivo y la grabación estará disponible durante 30 días en el sitio web de la compañía.
Cue Biopharma (나스닥: CUE)는 2025년 5월 8일 뉴욕에서 열리는 Citizens Life Sciences Conference에서 파이어사이드 채팅에 참여한다고 발표했습니다. CEO 다니엘 파세리는 동부시간 기준 오전 11시부터 11시 25분까지 Immuno-STAT™ 플랫폼 프로그램의 진행 상황을 발표할 예정이며, 여기에는 CUE-100 시리즈, CUE-401, CUE-501이 포함됩니다. 발표에서는 CUE-501에 대한 Boehringer Ingelheim과의 최근 협력이 강조되며, 이는 자가면역 및 염증 질환 치료를 위한 T세포 매개 특정 B세포 표적 제거에 중점을 둡니다. 라이브 웹캐스트가 제공되며, 녹화본은 회사 웹사이트에서 30일간 아카이브됩니다.
Cue Biopharma (Nasdaq : CUE) a annoncé sa participation à une discussion informelle lors de la Citizens Life Sciences Conference à New York le 8 mai 2025. Le PDG Daniel Passeri présentera de 11h00 à 11h25 EDT, abordant les avancées des programmes de la plateforme Immuno-STAT™, incluant la série CUE-100, CUE-401 et CUE-501. La présentation mettra en lumière leur récent partenariat avec Boehringer Ingelheim pour le CUE-501, axé sur la déplétion ciblée des cellules B spécifiques médiée par les cellules T pour le traitement des maladies auto-immunes et inflammatoires. Un webcast en direct sera disponible, et l’enregistrement sera archivé pendant 30 jours sur le site web de l’entreprise.
Cue Biopharma (Nasdaq: CUE) gab bekannt, dass es an einem Fireside-Chat auf der Citizens Life Sciences Conference in New York am 8. Mai 2025 teilnehmen wird. CEO Daniel Passeri wird von 11:00 bis 11:25 Uhr EDT präsentieren und dabei Fortschritte bei den Immuno-STAT™-Plattformprogrammen, einschließlich der CUE-100-Serie, CUE-401 und CUE-501, erläutern. Die Präsentation wird die kürzlich eingegangene Partnerschaft mit Boehringer Ingelheim für CUE-501 hervorheben, die sich auf die T-Zell-vermittelte gezielte Eliminierung spezifischer B-Zellen zur Behandlung von Autoimmun- und Entzündungskrankheiten konzentriert. Ein Live-Webcast wird verfügbar sein, und die Aufzeichnung wird für 30 Tage auf der Website des Unternehmens archiviert.
- None.
- None.
BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will participate in a fireside chat at the Citizens Life Sciences Conference being held in New York, May 7-8, 2025.
During the fireside chat, Cue Biopharma will discuss progress on its programs from the Immuno-STAT™ platform including the CUE-100 series, CUE-401, and CUE-501, which was recently partnered with Boehringer Ingelheim for T cell mediated targeted depletion of specific B cells to address autoimmune and inflammatory diseases.
Citizens Life Sciences Conference
Presentation Date: Thursday, May 8, 2025
Presentation Time: 11:00 a.m. EDT – 11:25 a.m. EDT
Presenter: Daniel Passeri, Chief Executive Officer
Webcast Link: https://wsw.com/webcast/jmp64/cue/1531757
A live and archived webcast of the fireside chat will be available in the News and Publications section of the Company’s website. The webcast will be archived for 30 days.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and protein engineering as well as the design and clinical development of protein biologics.
For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
FAQ
When is Cue Biopharma (CUE) presenting at the Citizens Life Sciences Conference 2025?
What will Cue Biopharma discuss during their Citizens Life Sciences Conference presentation?
Who is presenting for Cue Biopharma at the Citizens Life Sciences Conference?
What is the recent partnership between Cue Biopharma (CUE) and Boehringer Ingelheim?
